Applied Clinical Trials Online3d
Johnson & Johnson Releases New Data from Phase III MARIPOSA Trial of Rybrevant-Lazcluze Combination in Non-Small Cell Lung Cancer
Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.
Fierce Pharma3d
J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca's Tagrisso
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...
Lutris Pharma to Present at the American Association for Cancer Research Annual Meeting 2025
Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...
Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...
Le Lézard4d
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the ...
Le Lézard4d
TOLREMO Strengthens Scientific Advisory Board with Lung Cancer Expert Pasi A. Jänne
TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Pasi A. Jänne, M.D., PhD, a world renowned translational thoracic medical oncologist, to its Scientific Advisory Board (SAB).
Memorial Sloan Kettering Cancer Center6d
New Targeted Therapy Strategies for Addressing Non-Small Cell Lung Cancer Metastatic Disease
Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...